TY - JOUR. T1 - Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain. AU - Shu, Hui Kuo G.. AU - Chang, Chi Ming. AU - Ravi, Lakshmeswari. AU - Ling, Lei. AU - Castellano, Chris M.. AU - Walter, Elizabeth. AU - Pelley, Robert J.. AU - Kung, Hsing Jien. PY - 1994/1/1. Y1 - 1994/1/1. N2 - Avian c-erbB is activated to a leukemia oncogene following truncation of its amino-terminal ligand-binding domain by retroviral insertion. The insertionally activated transcripts encode protein products which have constitutive tyrosine kinase activity and can induce erythroleukemia but not sarcomas. We have previously found that a valine-to-isoleucine point mutation at position 157 (V157I mutant) within the tyrosine kinase domain of this truncated erbB can dramatically activate the sarcomagenic potential of the oncogene and increase the kinase activity of this oncoprotein. This mutation lies at position 157 of the insertionally activated ...
Base Sequence; Cloning, Molecular; Escherichia coli; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Oncogene Proteins v-erbB; Plasmids; Polymerase Chain Reaction; Retroviridae Proteins, Oncogenic. ...
The four members of the ERBB (HER) family of transmembrane receptor tyrosine kinases are frequently activated in cancer by several mechanisms, such as mutation, amplification, or autocrine ligand-receptor stimulation. We recently identified gene fusions involving the ERBB ligand gene, NRG1, which represent a novel mechanism for ERBB pathway deregulation. These fusions lead to expression and presentation of the EGF-like domain of NRG1 on the cell surface, which binds to ERBB3 in an autocrine and juxtacrine manner, thus inducing the formation of ERBB2-ERBB3 heterodimers, and subsequent activation of the PI3K-AKT and MAPK signaling pathways. These fusion genes were exclusively detected in lung adenocarcinomas of never smokers of the invasive mucinous subtype, which usually presents as a multifocal and unresectable disease, for which no effective treatment exists. Considering the large amount of drugs that target ERBB2 (HER2) and ERBB3 (HER3), and which are currently in different stages of clinical ...
The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-GEF P-Rex1. As the Jak2/Stat3 pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNAi, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector ROCK in breast cancer cells and induces the formation of stress fibers. ...
U.S., March 2 -- ClinicalTrials.gov registry received information related to the study (NCT03065387) titled Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation on Feb. 22. Brief Summary: There are 2 parts to this clinical research study: Part 1 (dose escalation) and Part 2 (expansion). The goal of Part 1 of this study is to find the highest tolerable dose of neratinib in combination with everolimus, Ibrance (palbociclib), or trametinib that can be given to patients who have advanced cancer with a specific mutation (EGFR, HER2, HER3, or HER4). The goal of Part 2 of this study is to learn if the dose of neratinib in combination with everolimus, Ibrance (palbociclib), or trametinib found in Part 1 can help to control advanced cancer in patients who have a specific mutation. The safety of this drug will also be studied in both parts of ...
Existence of signaling interactions between MET and the ERBBs is well established, but mechanism(s) are incompletely understood. For reconstruction of defined sets of receptors, it was essential to use a receptor-null cell background, which was not possible for epithelial lines as they express one or more ERBBs. We used murine 32D cells, which do not express endogenous MET or any ERBBs, to investigate interactions between MET and individual ERBBs. EGFR signaling was sufficient to induce MET phosphorylation and increase MET protein levels, but MET activation was augmented by coexpression of ERBB3. Rather than direct cross-phosphorylation, EGFR activation of MET occurs through combined stabilization of MET protein and intermediary signaling through MAPK. EGFR-MET cross-talk in lung cancer cells is more complex, and involves multiple levels of regulation including RNA, protein, and phosphorylation. Significantly, in lung carcinoma, EGFR-MET signaling is exaggerated in metastatic cells where MET ...
inproceedings{444095, author = {Stove, Christophe and Boterberg, Tom and Derycke, Lara and VANDEKERKHOVE, D and Mareel, Marcus and Bracke, Marc}, booktitle = {Acta Clinica Belgica}, issn = {0001-5512}, pages = {205--205}, title = {An anti-invasive factor in the conditioned medium of a melanoma cell line: signaling via the ErbB receptors?}, volume = {58}, year = {2001 ...
There are 2 parts to this clinical research study: Part 1 (dose escalation) and Part 2 (expansion). The goal of Part 1 of this study is to find the highest
The ErbB protein family or epidermal growth factor receptor (EGFR) family is a family of four structurally related receptor tyrosine kinases. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimers Disease. In mice loss of signaling by any member of the ErbB family results in embryonic lethality with defects in organs including the lungs, skin, heart and brain. Excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor. ErbB-1 and ErbB-2 are found in many human cancers and their excessive signaling may be critical factors in the development and malignancy of these tumors. The ErbB protein family consists of 4 members ...
(2013) Schokoroy et al. PLoS ONE. Background:The ErbB receptors, Ras proteins and nucleolin are major contributors to malignant transformation. The pleiotropic protein nucleolin can bind to both Ras protein and ErbB receptors. Previously, we have demonstrated a crosstalk between Ras, nucleolin an...
High-quality ErbB3 proteins from ACROBiosystems. Various species and tags of ErbB3 proteins. Minimal Batch-to-Batch Variation. Bulks in stock.
A DNA fragment distinct from the epidermal growth factor receptor (EGF-R) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64 % and 67 % to a contiguous region within the tyrosine kinase domains of the EGF-R and erbB-2 proteins, respectively, cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGF-R and erbB-2, plays a role in some human malignancies.
Description of disease Erythroblastosis fetalis. Treatment Erythroblastosis fetalis. Symptoms and causes Erythroblastosis fetalis Prophylaxis Erythroblastosis fetalis
ERG antibody, Internal (v-ets avian erythroblastosis virus E26 oncogene homolog) for WB. Anti-ERG pAb (GTX77743) is tested in Human samples. 100% Ab-Assurance.
Plasmid MSCV-human Erbb2-IRES-GFP from Dr. Martine Roussels lab contains the insert Erbb2 and is published in Cell Rep. 2017 Mar 21;18(12):2907-2917. doi: 10.1016/j.celrep.2017.02.073. This plasmid is available through Addgene.
人ErbB2 ELISA试剂盒ELISA试剂盒datasheet (ab100510).Abcam抗体、ELISA、激动剂拮抗剂、表观遗传试剂、蛋白多肽,使用效果保证,中国70%以上现货。
Looking for Erythroblastosis faetalis? Find out information about Erythroblastosis faetalis. a disease manifested at birth or shortly thereafter and generally caused by incompatibility of the mothers blood with that of the fetus with respect to the... Explanation of Erythroblastosis faetalis
At the first baby, there are no antibodies against Rh+, while birth, blood of the baby and the mother mixes and there are some antibodies produced, And those antibodies make the second baby die or born with some abnormalities. IgG can pass through placenta. Actually erythroblastosis fetalis can also be defined as the lysis of fetal RBCs by maternal IgGs ...
BioAssay record AID 726209 submitted by ChEMBL: Inhibition of human recombinant DAO expressed in G418-resistant HEK293/NEO cells assessed as effect on D-alanine level at 17 uM incubated for 30 mins prior to D-alanine addition measured after 24 hrs by HPLC analysis relative to vehicle-treated control.
|p|Description:|br /|IC50: AZD8931 showed equipotent, reversible inhibition of EGFR (IC50, 4 nmol/L), erbB2 (IC50, 3 nmol/L), and erbB3 (IC50, 4 nmol/L) phosphorylation in cells|br /|The erbB receptor family is composed of four related receptor tyrosine k
Applications Treatment of cancers that possess the ErbB receptors (e.g. colorectal, liver, bladder, and head and neck tumors)Advantages
The selective erbB2 antagonist AG825 dampens the NRG1α-induced MRVA.Administration of AG825 in DMSO vehicle (n = 5) caused a robust, dose-dependent decreas
Define erythroblastosis fetalis. erythroblastosis fetalis synonyms, erythroblastosis fetalis pronunciation, erythroblastosis fetalis translation, English dictionary definition of erythroblastosis fetalis. n. A severe hemolytic disease of a fetus or newborn infant caused by the production of maternal antibodies against the fetal red blood cells, usually...
The proto- oncogene c- erbB- 1 codes for the epidermal growth factor receptor. Its name originates from the viral homolog v- erbB which was isolated from an avian erythroblastosis virus ( AEV) where it was contained as a fragment of the chicken c- ErbB- 1 gene lacking the amino- terminal ligand- binding domain. Overexpression of erbB- 1 genes occurs in a wide range of tumors, commonly squamous carcinomas of various sites and less commonly adenocarcinomas. The human c- erbB- 1 gene is located in the chromosomal region 7p14 and 7p12 ...
Erythroblastosis fetalis occurs due to Rh incompatibility between the mother and the fetus, resulting in severe anemia and sometimes death of the fetus.
ERG antibody [N3C3] (v-ets erythroblastosis virus E26 oncogene homolog (avian)) for WB. Anti-ERG pAb (GTX113079) is tested in Human, Mouse samples. 100% Ab-Assurance.
The ErbB family of receptor tyrosine kinases includes EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Abundant evidence supports the causal role of HER2 overexpres...
In our study, the first to examine the relationship between PA and LV trabeculation extent in a community-based cohort using CMR imaging, the following observations were made. First, there was no linear relationship between PA and maximal NC/C ratio for both PA measurement methods. Second, there was no significant difference in maximal NC/C ratio between the lowest and highest PA extreme groups for both PA measurement methods. Third, PA (measured in total MET-min/week) augmented the negative relationship between LVEF and maximal NC/C ratio. Finally, age and LVEDV exhibited a significantly positive linear relationship with maximal NC/C ratio, while male sex, BMI, LV mass and LVEF exhibited a significantly negative linear relationship with maximal NC/C ratio.. Studies that previously hypothesised that LV trabeculation extent may participate in the exercise-induced cardiac remodelling process using models of pregnancy and extreme athletically trained PA levels found increased trabeculation extent ...
The importance of ErbB receptors in development is proven from the analysis of genetically modified mice. Indeed, null mutations in individual ErbB loci are lethal. More specifically, depending upon the genetic background of the host, loss of ErbB1 leads to embryonic or perinatal lethality with mice showing abnormalities in multiple organs including the brain, skin, lung and gastrointestinal tract (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995; Sibilia et al., 1998). ErbB2 null mice die at midgestation (E10.5) due to trabeculae malformation in the heart (Lee et al., 1995), a phenotype that is shared by ErbB4 knockout mice (Gassmann et al., 1995). In addition, through genetic rescue of heart development via myocardial expression of an ErbB2 transgene, a further role for ErbB2 in peripheral nervous system development has been demonstrated (Morris et al., 1999). In the case of ErbB3, most knockout mice die by E13.5, displaying normal heart trabeculation but defective ...
Complete information for ERBB2 gene (Protein Coding), Erb-B2 Receptor Tyrosine Kinase 2, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium